Roche Holding AG (RO, ROG,RHHBY) on Wednesday announced that it has received CE mark for its Elecsys Dengue Ag test - a high-throughput, fully automated immunoassay to be used as an aid in the diagnosis of an acute dengue virus infection.
The Elecsys Dengue Ag is an in-vitro diagnostic immunoassay for the qualitative detection of the NS1 antigen of the dengue virus in human serum and plasma, a key marker of acute infection during the first days of illness.
It is intended for use on Roche's fully automated cobas e immunoassay analysers: cobas e 801 systems and cobas e 402 platforms - a widely used platform with an extensive installed base in laboratories worldwide.
The test has been shown to reliably detect NS1 antigen for all four dengue virus serotypes - DENV-1, DENV-2, DENV-3, and DENV-4.
In clinical studies, it demonstrated 94.90 percent sensitivity in PCR-confirmed positive samples and 99.96 percent relative specificity in a large cohort of healthy blood donors.
The Elecsys Dengue Ag test is expected to provide reliable and fast results, enhanced efficiency and traceability as well as a comprehensive response across the entire patient journey.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.